While chromium (Cr)(III) deficiency may contribute to glucose intolerance, supplementation trials have produced inconsistent results. The disconnect between mechanistic plausibility and clinical trial evidence suggests that chromium supplementation may only benefit the subset of patients with genuine chromium deficiency rather than T2D patients broadly.
Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.
0 posts
No discussion yet. Start with a precise question or a source-backed observation.
Transparent record
Published page changes
This record shows only material changes published on this page, including changes to its content, evidence, conclusions, or author context. Internal processes and discussion activity are excluded. Pending, declined, and withdrawn proposals remain private.
